Insights

Innovative Vaccine Technology TheraVectys is a biotechnology company pioneering novel lentiviral vector technology for therapeutic vaccines. This technology offers a unique selling point for targeting unmet medical needs in cancer and infectious diseases treatment and prevention.

Recent Funding Boost TheraVectys recently secured $20M in funding, indicating strong financial backing and potential for expanded research and development efforts. This funding injection presents an opportunity for partnership or investment collaboration with interested stakeholders.

Experienced Leadership The appointment of Alain Clergeot, MD, as TheraVectys' Chief Executive Officer brings valuable leadership experience in the biotech industry. Leveraging this leadership strength can facilitate strategic partnerships or collaborations with other industry players.

Joint-Laboratory Partnership TheraVectys has a unique joint-laboratory collaboration with the prestigious Institut Pasteur in Paris, enhancing the company's credibility and research capabilities. Leveraging this partnership can open doors for collaborative projects or technology transfer opportunities.

Technology Stack and Market Positioning TheraVectys employs a diverse tech stack including jsDelivr, Google Maps, and Modernizr, showcasing a commitment to technological advancement. Understanding and aligning with the company's tech solutions can provide avenues for tailored product offerings or tech partnerships.

THERAVECTYS Tech Stack

THERAVECTYS uses 8 technology products and services including jsDelivr, RSS, Twitter Emoji (Twemoji), and more. Explore THERAVECTYS's tech stack below.

  • jsDelivr
    Content Delivery Network
  • RSS
    Content Management System
  • Twitter Emoji (Twemoji)
    Font Scripts
  • Google Font API
    Font Scripts
  • OWL Carousel
    Javascript Libraries
  • Modernizr
    Javascript Libraries
  • Google Maps
    Maps
  • Microsoft IIS
    Web Servers

THERAVECTYS's Email Address Formats

THERAVECTYS uses at least 1 format(s):
THERAVECTYS Email FormatsExamplePercentage
FLast@theravectys.comJDoe@theravectys.com
44%
First.Last@theravectys.comJohn.Doe@theravectys.com
11%
FMiddleLast@theravectys.comJMichaelDoe@theravectys.com
1%
FLast@theravectys.comJDoe@theravectys.com
44%

Frequently Asked Questions

Where is THERAVECTYS's headquarters located?

Minus sign iconPlus sign icon
THERAVECTYS's main headquarters is located at 28, Rue du Docteur Roux Paris, Île-de-France 75015 FR. The company has employees across 3 continents, including EuropeNorth AmericaAsia.

What is THERAVECTYS's phone number?

Minus sign iconPlus sign icon
You can contact THERAVECTYS's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is THERAVECTYS's official website and social media links?

Minus sign iconPlus sign icon
THERAVECTYS's official website is theravectys.com and has social profiles on LinkedIn.

How much revenue does THERAVECTYS generate?

Minus sign iconPlus sign icon
As of January 2025, THERAVECTYS's annual revenue reached $3.8M.

What is THERAVECTYS's SIC code NAICS code?

Minus sign iconPlus sign icon
THERAVECTYS's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does THERAVECTYS have currently?

Minus sign iconPlus sign icon
As of January 2025, THERAVECTYS has approximately 18 employees across 3 continents, including EuropeNorth AmericaAsia. Key team members include Chief Medical Officer: C. B.Chief Representative: A. H.Trilingual Executive Assistant To CEO: J. L.. Explore THERAVECTYS's employee directory with LeadIQ.

What industry does THERAVECTYS belong to?

Minus sign iconPlus sign icon
THERAVECTYS operates in the Biotechnology Research industry.

What technology does THERAVECTYS use?

Minus sign iconPlus sign icon
THERAVECTYS's tech stack includes jsDelivrRSSTwitter Emoji (Twemoji)Google Font APIOWL CarouselModernizrGoogle MapsMicrosoft IIS.

What is THERAVECTYS's email format?

Minus sign iconPlus sign icon
THERAVECTYS's email format typically follows the pattern of . Find more THERAVECTYS email formats with LeadIQ.

How much funding has THERAVECTYS raised to date?

Minus sign iconPlus sign icon
As of January 2025, THERAVECTYS has raised $20M in funding. The last funding round occurred on Feb 08, 2021 for $20M.

When was THERAVECTYS founded?

Minus sign iconPlus sign icon
THERAVECTYS was founded in 2005.
THERAVECTYS

THERAVECTYS

Biotechnology ResearchÎle-de-France, France11-50 Employees

Based in Paris and in the USA, TheraVectys is an immunotherapy company spun off from the Institut Pasteur created in 2005 by Dr. Pierre Charneau.

TheraVectys is pioneering the application of novel lentiviral vector technology to address most of unmet and critical medical needs.

By creating the only Joint-Laboratory between a private company and the Institut Pasteur in Paris, TheraVectys develops an extensive pipeline of vaccine candidates to drive the widespread treatment and prevention of cancer and infectious diseases.

Leveraging our proprietary technology platform, and the extensive virology expertise of the Institut Pasteur, TheraVectys provides a robust and highly effective transfection mechanism to elicit a potent and targeted immune response previously unseen.

Section iconCompany Overview

Headquarters
28, Rue du Docteur Roux Paris, Île-de-France 75015 FR
Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2005
Employees
11-50

Section iconFunding & Financials

  • $20M

    THERAVECTYS has raised a total of $20M of funding over 4 rounds. Their latest funding round was raised on Feb 08, 2021 in the amount of $20M.

  • $10M

    THERAVECTYS's revenue is in the range of $10M

Section iconFunding & Financials

  • $20M

    THERAVECTYS has raised a total of $20M of funding over 4 rounds. Their latest funding round was raised on Feb 08, 2021 in the amount of $20M.

  • $10M

    THERAVECTYS's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.